Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16831105 | 1.00 | PRKCI (0.32) | PRKCIPTGER4ALDH1A1MAPT | |
| SCHEMBL16831571 | 0.78 | PTGER4 (0.39) | PTGER4ALDH1A1MAPT | |
| SCHEMBL29442635 | 0.78 | PTGER4 (0.39) | PTGER4ALDH1A1MAPT | |
| SCHEMBL27298134 | 0.77 | CA1 (0.33) | PRKCIPTGER4 | |
| SCHEMBL16831157 | 0.77 | PTGER4 (0.53) | PRKCIPTGER4ALDH1A1 | |
| SCHEMBL30620243 | 0.77 | CA1 (0.33) | PRKCIPTGER4 | |
| SCHEMBL29818977 | 0.76 | PTGER4 (0.38) | PTGER4ALDH1A1MAPT | |
| SCHEMBL21713733 | 0.76 | PTGER4 (0.38) | PTGER4ALDH1A1MAPT | |
| SCHEMBL20439755 | 0.75 | IDO1 (0.38) | PTGER4ALDH1A1MAPT | |
| SCHEMBL26654848 | 0.74 | ALOX5AP (0.36) | PRKCIMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118206566-A | Hydroxypyridooxazepine as NRF2 activator | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-113474349-B | Hydroxypyridooxazepine as NRF2 activator | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | PRKCI 2194/4885PTGER4 1167/4885ALDH1A1 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.